Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is anticipated to announce its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($55.80) per share for the quarter.
Enveric Biosciences Stock Performance
Shares of ENVB opened at $1.97 on Thursday. The firm has a market cap of $2.74 million, a P/E ratio of -0.05 and a beta of 0.31. Enveric Biosciences has a 52 week low of $1.82 and a 52 week high of $19.92. The firm’s 50-day simple moving average is $2.59 and its 200 day simple moving average is $5.23.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Enveric Biosciences presently has a consensus rating of “Sell”.
About Enveric Biosciences
Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.
Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.
Recommended Stories
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
